SEC For	m 4 FORM	4	UNITED	STA	TES S	SECU						NG	EC	OMN	/IS	SION					
			Washington, D.C. 20549												OMB APPROVAL						
Section obligati	this box if no lo 16. Form 4 or ons may contin tion 1(b).	Pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940													OMB Number: 3235-0287 Estimated average burden hours per response: 0.5						
1. Name and Address of Reporting Person [*] Strem Brian M.					KIO	2. Issuer Name and Ticker or Trading Symbol <u>KIORA PHARMACEUTICALS INC</u> [KPRX]									5. Relationship of Rep (Check all applicable) X Director X Officer (give			g Pers	uer vner specify		
(Last)(First)(Middle)C/O KIORA PHARMACEUTICALS, INC1371 E. 2100 SOUTH, SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 10/21/2022										Λ	below)	Presiden	t and	below) CEO		
(Street) SALT LA CITY	SALT LAKE UT 84105				4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)									. Indi ine) X	' I					
(City) (State) (Zip)																					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				ction 2A. Deemed Execution Date,		, 3 , T	3. Transaction Code (Instr.		4. Securities Acquired (A)			d (A) or) or 5. Amount of		s ally ollowing	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code \	/	Amount		(A) or (D)	Pric	e	Transact (Instr. 3 a	ion(s)			(1130.4)	
Common Stock 10				10/21	/2022				Α		12,500 ⁽¹⁾ A		Α	\$	5 <mark>0</mark>) 13,183			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any			Date, Ti C	4. Transaction Code (Instr. 8)		of E		5. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amc of Securities Underlying Derivative Secu (Instr. 3 and 4)			Derivative Security ity (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
														Amour or Numbe							

Option (right to 10/21/2022 \$<mark>6.78</mark> buy)

Explanation of Responses:

Stock

1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of October 21, 2023, October 21, 2024 and October 21, 2025, subject to the reporting person's continuous service through each such vesting date.

Date Exercisable

(2)

Expiration Date

10/21/2032

Title

Common Stock

2. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on October 21, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

/s/ Melissa Tosca, Attorney-in-10/25/2022 Fact

** Signature of Reporting Person Date

of Shares

18,750

\$<mark>0</mark>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

v

Code

A

(A)

18,750

(D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

18,750

D